Korro Bio (NASDAQ:KRRO) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS

by · The Cerbat Gem

Korro Bio (NASDAQ:KRRO – Get Free Report) announced its earnings results on Tuesday. The company reported ($2.26) earnings per share for the quarter, beating the consensus estimate of ($2.33) by $0.07, Zacks reports. The business had revenue of $2.27 million for the quarter.

Korro Bio Stock Down 3.6 %

Shares of KRRO stock opened at $24.17 on Wednesday. Korro Bio has a one year low of $18.50 and a one year high of $98.00. The company’s 50-day simple moving average is $30.70 and its 200-day simple moving average is $41.82.

Analyst Ratings Changes

KRRO has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $115.00 target price on shares of Korro Bio in a research note on Friday, November 22nd. Oppenheimer began coverage on Korro Bio in a research note on Friday, January 10th. They set an “outperform” rating and a $155.00 target price for the company. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Korro Bio currently has a consensus rating of “Buy” and an average price target of $144.00.

Check Out Our Latest Analysis on KRRO

Korro Bio Company Profile

(Get Free Report)

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Read More